当前位置: 首页 >> 检索结果
1602. Design and validation of a patient-reported outcome measure scale in acute pancreatitis: the PAN-PROMISE study.
作者: Enrique de-Madaria.;Claudia Sánchez-Marin.;Irene Carrillo.;Santhi Swaroop Vege.;Serge Chooklin.;Andriy Bilyak.;Rafael Mejuto.;Violeta Mauriz.;Peter Hegyi.;Katalin Márta.;Ayesha Kamal.;Eugenia Lauret-Braña.;Sorin T Barbu.;Vitor Nunes.;M Lourdes Ruiz-Rebollo.;Guillermo García-Rayado.;Edgard E Lozada-Hernandez.;Jorge Pereira.;Ionut Negoi.;Silvia Espina.;Marcus Hollenbach.;Andrey Litvin.;Federico Bolado-Concejo.;Rómulo D Vargas.;Isabel Pascual-Moreno.;Vikesh K Singh.;José J Mira.
来源: Gut. 2021年70卷1期139-147页
This study aimed to develop and validate a patient-reported outcome measure (PROM) in acute pancreatitis (AP) as an endpoint centred on the patient.
1603. Aberrant gut microbiota alters host metabolome and impacts renal failure in humans and rodents.
作者: Xifan Wang.;Songtao Yang.;Shenghui Li.;Liang Zhao.;Yanling Hao.;Junjie Qin.;Lian Zhang.;Chengying Zhang.;Weijing Bian.;Li Zuo.;Xiu Gao.;Baoli Zhu.;Xin Gen Lei.;Zhenglong Gu.;Wei Cui.;Xiping Xu.;Zhiming Li.;Benzhong Zhu.;Yuan Li.;Shangwu Chen.;Huiyuan Guo.;Hao Zhang.;Jing Sun.;Ming Zhang.;Yan Hui.;Xiaolin Zhang.;Xiaoxue Liu.;Bowen Sun.;Longjiao Wang.;Qinglu Qiu.;Yuchan Zhang.;Xingqi Li.;Weiqian Liu.;Rui Xue.;Hong Wu.;DongHua Shao.;Junling Li.;Yuanjie Zhou.;Shaochuan Li.;Rentao Yang.;Oluf Borbye Pedersen.;Zhengquan Yu.;Stanislav Dusko Ehrlich.;Fazheng Ren.
来源: Gut. 2020年69卷12期2131-2142页
Patients with renal failure suffer from symptoms caused by uraemic toxins, possibly of gut microbial origin, as deduced from studies in animals. The aim of the study is to characterise relationships between the intestinal microbiome composition, uraemic toxins and renal failure symptoms in human end-stage renal disease (ESRD).
1604. Differential inflammasome activation predisposes to acute-on-chronic liver failure in human and experimental cirrhosis with and without previous decompensation.
作者: Sofia Monteiro.;Josephine Grandt.;Frank Erhard Uschner.;Nina Kimer.;Jan Lysgård Madsen.;Robert Schierwagen.;Sabine Klein.;Christoph Welsch.;Liliana Schäfer.;Christian Jansen.;Joan Claria.;José Alcaraz-Quiles.;Vicente Arroyo.;Richard Moreau.;Javier Fernandez.;Flemming Bendtsen.;Gautam Mehta.;Lise Lotte Gluud.;Søren Møller.;Michael Praktiknjo.;Jonel Trebicka.
来源: Gut. 2021年70卷2期379-387页
Systemic inflammation predisposes acutely decompensated (AD) cirrhosis to the development of acute-on-chronic liver failure (ACLF). Supportive treatment can improve AD patients, becoming recompensated. Little is known about the outcome of patients recompensated after AD. We hypothesise that different inflammasome activation is involved in ACLF development in compensated and recompensated patients.
1605. Effectiveness of one-time endoscopic screening programme in prevention of upper gastrointestinal cancer in China: a multicentre population-based cohort study.
作者: Ru Chen.;Yong Liu.;Guohui Song.;Bianyun Li.;Deli Zhao.;Zhaolai Hua.;Xinzheng Wang.;Jun Li.;Changqing Hao.;Liwei Zhang.;Shuzheng Liu.;Jialin Wang.;Jinyi Zhou.;Yongzhen Zhang.;Bo Li.;Yanyan Li.;Xiang Feng.;Lin Li.;Zhiwei Dong.;Wenqiang Wei.;Guiqi Wang.
来源: Gut. 2021年70卷2期251-260页
To estimate the effectiveness of endoscopic screening programme in reducing incidence and mortality of upper gastrointestinal cancer in high risks areas of China.
1608. Gastrointestinal symptoms of 95 cases with SARS-CoV-2 infection.
作者: Lu Lin.;Xiayang Jiang.;Zhenling Zhang.;Siwen Huang.;Zhenyi Zhang.;Zhaoxiong Fang.;Zhiqiang Gu.;Liangqing Gao.;Honggang Shi.;Lei Mai.;Yuan Liu.;Xianqi Lin.;Renxu Lai.;Zhixiang Yan.;Xiaofeng Li.;Hong Shan.
来源: Gut. 2020年69卷6期997-1001页
To study the GI symptoms in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infected patients.
1609. Early gastric cancer detection in high-risk patients: a multicentre randomised controlled trial on the effect of second-generation narrow band imaging.
作者: Naohiro Yoshida.;Hisashi Doyama.;Tomonori Yano.;Takahiro Horimatsu.;Noriya Uedo.;Yoshinobu Yamamoto.;Naomi Kakushima.;Hiromitsu Kanzaki.;Shinichiro Hori.;Kenshi Yao.;Ichiro Oda.;Chikatoshi Katada.;Chizu Yokoi.;Ken Ohata.;Kenichi Yoshimura.;Hideki Ishikawa.;Manabu Muto.
来源: Gut. 2021年70卷1期67-75页
Early detection of gastric cancer has been the topic of major efforts in high prevalence areas. Whether advanced imaging methods, such as second-generation narrow band imaging (2G-NBI) can improve early detection, is unknown.
1610. Practice of endoscopy during COVID-19 pandemic: position statements of the Asian Pacific Society for Digestive Endoscopy (APSDE-COVID statements).
作者: Philip Wai Yan Chiu.;Siew C Ng.;Haruhiro Inoue.;D Nageshwar Reddy.;Enqiang Ling Hu.;Joo Young Cho.;Lawrence Ky Ho.;David G Hewett.;Han-Mo Chiu.;Rungsun Rerknimitr.;Hsiu-Po Wang.;Shiaw Hooi Ho.;Dong Wan Seo.;Khean-Lee Goh.;Hisao Tajiri.;Seigo Kitano.;Francis K L Chan.
来源: Gut. 2020年69卷6期991-996页
Coronavirus-19 (COVID-19) caused by SARS-CoV-2 has become a global pandemic. Risk of transmission may occur during endoscopy and the goal is to prevent infection among healthcare professionals while providing essential services to patients. Asia was the first continent to have a COVID-19 outbreak, and this position statement of the Asian Pacific Society for Digestive Endoscopy shares our successful experience in maintaining safe and high-quality endoscopy practice at a time when resources are limited. Sixteen experts from key societies of digestive endoscopy in Asia were invited to develop position statements, including patient triage and risk assessment before endoscopy, resource prioritisation and allocation, regular monitoring of personal protective equipment, infection control measures, protective device training and implementation of a strategy for stepwise resumption of endoscopy services after control of the COVID-19 outbreak.
1611. Transition to quantitative faecal immunochemical testing from guaiac faecal occult blood testing in a fully rolled-out population-based national bowel screening programme.
作者: Gavin Clark.;Judith A Strachan.;Frank A Carey.;Thomas Godfrey.;Audrey Irvine.;Alisson McPherson.;Jess Brand.;Annie S Anderson.;Callum G Fraser.;Robert Jc Steele.
来源: Gut. 2021年70卷1期106-113页
Faecal immunochemical tests (FIT) are replacing guaiac faecal occult blood tests (FOBT) in colorectal cancer (CRC) screening. Data from the first year of FIT screening were compared with those from FOBT screening and assumptions based on a pilot evaluation of FIT.
1613. HBV vaccination and HBV infection induces HBV-specific natural killer cell memory.
作者: Ratna S Wijaya.;Scott A Read.;Naomi R Truong.;Shuanglin Han.;Dishen Chen.;Haleh Shahidipour.;Nicole L Fewings.;Stephen Schibeci.;Mahmoud K Azardaryany.;Grant P Parnell.;David Booth.;David van der Poorten.;Rita Lin.;Jacob George.;Mark W Douglas.;Golo Ahlenstiel.
来源: Gut. 2021年70卷2期357-369页
Vaccination against hepatitis B virus (HBV) confers protection from subsequent infection through immunological memory that is traditionally considered the domain of the adaptive immune system. This view has been challenged following the identification of antigen-specific memory natural killer cells (mNKs) in mice and non-human primates. While the presence of mNKs has been suggested in humans based on the expansion of NK cells following pathogen exposure, evidence regarding antigen-specificity is lacking. Here, we demonstrate the existence of HBV-specific mNKs in humans after vaccination and in chronic HBV infection.
1615. No difference in hepatocellular carcinoma risk between chronic hepatitis B patients treated with entecavir versus tenofovir.
Entecavir (ETV) and tenofovir disoproxil fumarate (TDF) are first-line agents for the treatment of chronic hepatitis B (CHB). Recent studies have challenged the assumption that these agents are equally effective at preventing hepatocellular carcinoma (HCC). We aimed to determine whether the risk of HCC and mortality differ in patients with CHB treated with ETV and TDF.
1618. Mortality in biopsy-proven alcohol-related liver disease: a population-based nationwide cohort study of 3453 patients.
作者: Hannes Hagström.;Maja Thiele.;Bjorn Roelstraete.;Jonas Söderling.;Jonas F Ludvigsson.
来源: Gut. 2021年70卷1期170-179页
Patients with alcohol-related liver disease (ALD) are at increased risk of death, but studies have rarely investigated the significance of histological severity or estimated relative risks compared with a general population. We examined mortality in a nationwide cohort of biopsy-proven ALD.
1619. Population impact of direct-acting antiviral treatment on new presentations of hepatitis C-related decompensated cirrhosis: a national record-linkage study.
作者: Sharon J Hutchinson.;Heather Valerio.;Scott A McDonald.;Alan Yeung.;Kevin Pollock.;Shanley Smith.;Stephen Barclay.;John F Dillon.;Raymond Fox.;Peter Bramley.;Andrew Fraser.;Nicholas Kennedy.;Rory N Gunson.;Kate Templeton.;Hamish Innes.;Allan McLeod.;Amanda Weir.;Peter C Hayes.;David Goldberg.
来源: Gut. 2020年69卷12期2223-2231页
Population-based studies demonstrating the clinical impact of interferon-free direct-acting antiviral (DAA) therapies are lacking. We examined the impact of the introduction of DAAs on HCV-related decompensated cirrhosis (DC) through analysis of population-based data from Scotland.
1620. Targeting clinical epigenetic reprogramming for chemoprevention of metabolic and viral hepatocellular carcinoma.
作者: Frank Jühling.;Nourdine Hamdane.;Emilie Crouchet.;Shen Li.;Houssein El Saghire.;Atish Mukherji.;Naoto Fujiwara.;Marine A Oudot.;Christine Thumann.;Antonio Saviano.;Armando Andres Roca Suarez.;Kaku Goto.;Ricard Masia.;Mozhdeh Sojoodi.;Gunisha Arora.;Hiroshi Aikata.;Atsushi Ono.;Parissa Tabrizian.;Myron Schwartz.;Stephen J Polyak.;Irwin Davidson.;Christian Schmidl.;Christoph Bock.;Catherine Schuster.;Kazuaki Chayama.;Patrick Pessaux.;Kenneth K Tanabe.;Yujin Hoshida.;Mirjam B Zeisel.;François Ht Duong.;Bryan C Fuchs.;Thomas F Baumert.
来源: Gut. 2021年70卷1期157-169页
Hepatocellular carcinoma (HCC) is the fastest-growing cause of cancer-related mortality with chronic viral hepatitis and non-alcoholic steatohepatitis (NASH) as major aetiologies. Treatment options for HCC are unsatisfactory and chemopreventive approaches are absent. Chronic hepatitis C (CHC) results in epigenetic alterations driving HCC risk and persisting following cure. Here, we aimed to investigate epigenetic modifications as targets for liver cancer chemoprevention.
|